Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.57 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19146407 | 1.00 | ADORA3 (0.57) | ADORA3AHCYTLR7 | |
| SCHEMBL19129592 | 0.87 | ADORA3 (0.41) | ADORA3 | |
| SCHEMBL19124228 | 0.87 | ADORA3 (0.41) | ADORA3 | |
| SCHEMBL19146605 | 0.87 | ADORA3 (0.41) | ADORA3 | |
| SCHEMBL19130140 | 0.82 | ADORA3 (0.57) | ADORA3 | |
| SCHEMBL19145999 | 0.82 | ADORA3 (0.57) | ADORA3 | |
| SCHEMBL2128315 | 0.80 | AHCY (0.55) | ADORA3AHCYTLR7 | |
| SCHEMBL19130163 | 0.78 | ADORA3 (0.33) | ADORA3 | |
| SCHEMBL19124363 | 0.78 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL19129776 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885AHCY 457/4885TLR7 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.